This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Intapp (INTA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
INTAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy M-tron Industries, Inc. (MPTI) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MPTIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
New Strong Sell Stocks for August 30th
by Zacks Equity Research
AMKR, TECH and CIADY have been added to the Zacks Rank #5 (Strong Sell) List on August 30, 2024.
AMKRPositive Net Change TECHPositive Net Change CIADYPositive Net Change
biotechnology consumer-staples semiconductor
Expensify, Inc. (EXFY) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
EXFYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
by Zacks Equity Research
NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.
ALNYPositive Net Change NVSPositive Net Change LLYPositive Net Change EXELPositive Net Change
biotechnology medical pharmaceuticals
Addex Stock Soars on Crucial Update From Indivior Research Deal
by Zacks Equity Research
ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.
JNJNegative Net Change FULCPositive Net Change ADXNPositive Net Change INDVPositive Net Change
biotechnology biotechs medical pharmaceuticals
Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
by Zacks Equity Research
SLNO stock gains 6.3% as FDA accepts regulatory filing for lead candidate, DCCR, to treat hyperphagia associated with PWS under Priority Review.
ACADPositive Net Change SLNOPositive Net Change FULCPositive Net Change BVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
by Ekta Bagri
Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.
REGNPositive Net Change LXRXPositive Net Change GLPGPositive Net Change RYTMPositive Net Change
biotechnology biotechs medical pharmaceuticals
Sony (SONY) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
SONYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
2 Must-Buy Medical Stocks With Strong Momentum
by Nalak Das
Two medical stocks with strong momentum and a favorable Zacks Rank are: DVA, ILMN.
DVANegative Net Change ILMNPositive Net Change
biotechnology medical
New Strong Buy Stocks for August 28th
by Zacks Equity Research
BPMUF, QFIN, CRNC, SN and PINE have been added to the Zacks Rank #1 (Strong Buy) List on August 28, 2024.
SNPositive Net Change BPMUFPositive Net Change QFINPositive Net Change CRNCPositive Net Change PINENegative Net Change
biotechnology business-services computers consumer-discretionary reit
Roche Obtains Approval For its Rare Blood Disorder Drug in the EU
by Zacks Equity Research
RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.
AZNPositive Net Change RHHBYNegative Net Change LLYPositive Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
by Zacks Equity Research
REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
REGNPositive Net Change SNYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids
by Zacks Equity Research
RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.
ARCTPositive Net Change RYTMPositive Net Change FULCPositive Net Change BVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy GeoVax Labs Inc. (GOVX) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
GOVXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Distribution Solutions Group (DSGR) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
DSGRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
5 Best Small-Cap Stocks to Benefit From Interest Rate Cuts
by Nalak Das
We have narrowed our search to five small-cap stocks that have strong momentum. These are FULC, HRTG, SWIM, SHIP and BWAY.
HRTGPositive Net Change SHIPPositive Net Change BWAYNegative Net Change FULCPositive Net Change SWIMNegative Net Change
biotechnology construction insurance medical transportation
Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
by Zacks Equity Research
While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.
GSKNegative Net Change GILDPositive Net Change MRUSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.
ILMNPositive Net Change
biotechnology medical
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
by Zacks Equity Research
Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.
ARCTPositive Net Change STROPositive Net Change FULCPositive Net Change BVSPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Klaviyo, Inc. (KVYO) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
KVYOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Genpact (G) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
GNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BeiGene, Ltd. (BGNE) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
BGNEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
by Zacks Equity Research
Alnylam's (ALNY) Amvuttra and Givlaari sales continue to boost revenues. However, its reliance on collaboration partners and stiff competition remain concerns.
REGNPositive Net Change ALNYPositive Net Change NVSPositive Net Change RHHBYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bayer (BAYRY) Starts Mid-Stage Study on Chronic Kidney Disease Drug
by Zacks Equity Research
Bayer (BAYRY) advances its pipeline candidate BAY3283142 into phase II for the treatment of chronic kidney disease.
LLYPositive Net Change BAYRYPositive Net Change EXELPositive Net Change
biotechnology medical pharmaceuticals